Buspirone in Parkinson's Disease

Inclusion Criteria:

- Diagnosis of idiopathic PD by UK Parkinson's Disease Society Brain Bank Clinical
Diagnostic Criteria

- Significant anxiety as determined by the self-rated Parkinson Anxiety Scale (score ≥
14)

- Able to provide written informed consent

- At least 18 years of age

Exclusion Criteria:

- Diagnosis of atypical or secondary parkinsonism

- Concomitant treatment with an MAO inhibitor within the 14 days prior to screening
visit

- Significant renal or hepatic impairment

- Significant cognitive impairment defined as MOCA score < 23

- On-going depression with suicidal or homicidal ideation and concern for patient safety
based on clinical determination by the investigator

- Allergy or intolerance to study drug, matching placebo, or their formulations

- History of prior exposure to study drug

- Lactating or pregnant woman

- Concomitant treatment with a disallowed medication (detailed in section 6.2)

- Active drug or alcohol use or dependence that, in the opinion of the investigator,
would interfere with adherence to study requirements

- Concomitant treatment with an anxiolytic or antidepressant will be allowed however
potential participants who had dosage changes in the 30 days prior to the screening
visit will be excluded

- Use of an investigational drug within 30 days prior to screening visit

- Any medical or psychiatric comorbidity that, in the opinion of the investigator, would
compromise study participation

- Dysphagia defined as a score of ≥ 2 on MDS-UPDRS Item 2.3 Chewing and Swallowing